Arch Therapeutics Inc (ARTH) Given Average Rating of “Buy” by Brokerages
Arch Therapeutics Inc (NASDAQ:ARTH) has been assigned an average rating of “Buy” from the six research firms that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $2.83.
Several equities research analysts have commented on ARTH shares. Roth Capital set a $3.00 target price on shares of Arch Therapeutics and gave the company a “buy” rating in a research note on Thursday, May 25th. Zacks Investment Research raised shares of Arch Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 25th. ValuEngine raised shares of Arch Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 3rd. HC Wainwright set a $3.00 target price on shares of Arch Therapeutics and gave the company a “buy” rating in a research note on Monday, June 12th. Finally, Ifs Securities reaffirmed an “outperform” rating on shares of Arch Therapeutics in a research note on Tuesday, July 25th.
Shares of Arch Therapeutics (NASDAQ:ARTH) opened at 0.796535 on Friday. The firm’s 50 day moving average is $0.74 and its 200-day moving average is $0.60. Arch Therapeutics has a 52 week low of $0.41 and a 52 week high of $0.89. The firm’s market cap is $117.11 million.
About Arch Therapeutics
Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.
Receive News & Ratings for Arch Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.